Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Stoke Therapeutics, Inc. (STOK : NSDQ)
 
 • Company Description   
Stoke Therapeutics Inc. is a biopharmaceutical company. It develops antisense oligonucleotide medicines to treat genetic diseases. The company's product candidate consists of STK-001 which is to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics Inc. is based in Bedford, Massachusetts.

Number of Employees: 128

 
 • Price / Volume Information   
Yesterday's Closing Price: $33.00 Daily Weekly Monthly
20 Day Moving Average: 1,450,047 shares
Shares Outstanding: 54.80 (millions)
Market Capitalization: $1,808.31 (millions)
Beta: 1.24
52 Week High: $38.69
52 Week Low: $5.35
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 33.44% 29.29%
12 Week 151.14% 131.23%
Year To Date 199.18% 155.95%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
45 WIGGINS AVENUE
-
BEDFORD,MA 01730
USA		 ph: 781-430-8200
fax: -		 ir@stoketherapeutics.com http://www.stoketherapeutics.com
 
 • General Corporate Information   
Officers
Edward M. Kaye - Chief Executive Officer
Thomas E. Leggett - Chief Financial Officer
Julie A. Smith - Director
Adrian R. Krainer - Director
Jennifer C. Burstein - Director

Peer Information
Stoke Therapeutics, Inc. (CORR.)
Stoke Therapeutics, Inc. (RSPI)
Stoke Therapeutics, Inc. (CGXP)
Stoke Therapeutics, Inc. (BGEN)
Stoke Therapeutics, Inc. (GTBP)
Stoke Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 86150R107
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 06/01/25
Next Expected EPS Date: 11/04/25
Share - Related Items
Shares Outstanding: 54.80
Most Recent Split Date: (:1)
Beta: 1.24
Market Capitalization: $1,808.31 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.65 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $0.28 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 11/04/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 117.26
Trailing 12 Months: 38.82
PEG Ratio: -
Price Ratios
Price/Book: 5.38
Price/Cash Flow: -
Price / Sales: 9.05
EPS Growth
vs. Year Ago Period: 13.04%
vs. Previous Quarter: -121.05%
Sales Growth
vs. Year Ago Period: 186.01%
vs. Previous Quarter: -91.29%
ROE
09/30/25 - -
06/30/25 - 18.32
03/31/25 - 19.08
ROA
09/30/25 - -
06/30/25 - 15.48
03/31/25 - 15.72
Current Ratio
09/30/25 - -
06/30/25 - 6.98
03/31/25 - 8.41
Quick Ratio
09/30/25 - -
06/30/25 - 6.98
03/31/25 - 8.41
Operating Margin
09/30/25 - -
06/30/25 - 26.25
03/31/25 - 26.33
Net Margin
09/30/25 - -
06/30/25 - 26.25
03/31/25 - 26.33
Pre-Tax Margin
09/30/25 - -
06/30/25 - 26.90
03/31/25 - 27.00
Book Value
09/30/25 - -
06/30/25 - 6.13
03/31/25 - 6.41
Inventory Turnover
09/30/25 - -
06/30/25 - -
03/31/25 - -
Debt-to-Equity
09/30/25 - -
06/30/25 - 0.00
03/31/25 - 0.00
Debt-to-Capital
09/30/25 - -
06/30/25 - 0.00
03/31/25 - 0.00
 

Powered by Zacks Investment Research ©